Biogen Inc. ($BIIB) Stock Forecast: Down 5.1% Today

What is Biogen Inc.?

Biogen (NASDAQ: BIIB) is a biotechnology company specializing in neurological and neurodegenerative diseases, notably Alzheimer's disease treatments.

Why is Biogen Inc. going down?

BIIB stock is down 5.1% on May 6, 2025 18:26

• Following its Q1 earnings release, BIIB witnessed a significant decrease in stock value.
• BIIB outperformed earnings projections, posting an EPS of $3.02 compared to the estimated $2.52, and recorded a revenue surge to $2.43 billion, exceeding the expected $2.23 billion.
• Despite the positive earnings outcome, BIIB's stock faced a decline, potentially due to the mixed Q1 performance and the company's downward revision of its EPS guidance for the year.
• The market response to the revised guidance hints at apprehensions regarding future growth and performance, contributing to the bearish movement in BIIB's stock price today.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

4 Stocks to Buy for a Potential “Summer Panic” 

Tom Yeung here with your Sunday Digest.  Last month, I wrote about five stocks to “buy the dip.” Our quantitative systems signaled April’s selloff had gone too far and that low prices would be enough to trigger a market rally.  Since then, these five firms have performed splendidly, largely outperforming the S&P 500’s 8% rise. Salesforce Inc. (CRM) +16% Akamai Technologies Inc. (AKAM) +13% Advanced Micro Devices Inc. (AMD) +16% Moderna Inc. (MRNA) +6% Celanese Corp. (CE) +13% InvestorPlace Senior Analyst Luke Lango believes this is just the start.   He predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create a new summer “panic” of the sort not seen since 1997.  This is why he held a special 2025 Summer Panic Summit on Thursday. At this event, Luke explained why he believes this catalyst on May 7 will be a game-changer. Plus, he revealed a new set of stocks that he believes are primed to lead the next wave of growth. (You can watch a replay of the event here.)   Now, I can’t tell you what this catalyst is. You’ll have to see it for yourself in Luke’s special presentation. But if this panic buying he describes does take off, several of my top long-term picks are certain to benefit.   Let’s revisit two of them today – and a new one as well…

https://investorplace.com/2025/05/4-stocks-to-buy-for-a-potential-summer-panic/

4 Stocks to Buy for a Potential “Summer Panic” 

Tom Yeung here with your Sunday Digest.  Last month, I wrote about five stocks to “buy the dip.” Our quantitative systems signaled April’s selloff had gone too far and that low prices would be enough to trigger a market rally.  Since then, these five firms have performed splendidly, largely outperforming the S&P 500’s 8% rise. Salesforce Inc. (CRM) +16% Akamai Technologies Inc. (AKAM) +13% Advanced Micro Devices Inc. (AMD) +16% Moderna Inc. (MRNA) +6% Celanese Corp. (CE) +13% InvestorPlace Senior Analyst Luke Lango believes this is just the start.   He predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create a new summer “panic” of the sort not seen since 1997.  This is why he held a special 2025 Summer Panic Summit on Thursday. At this event, Luke explained why he believes this catalyst on May 7 will be a game-changer. Plus, he revealed a new set of stocks that he believes are primed to lead the next wave of growth. (You can watch a replay of the event here.)   Now, I can’t tell you what this catalyst is. You’ll have to see it for yourself in Luke’s special presentation. But if this panic buying he describes does take off, several of my top long-term picks are certain to benefit.   Let’s revisit two of them today – and a new one as well…

https://investorplace.com/smartmoney/2025/05/4-stocks-to-buy-for-a-potential-summer-panic/

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact - Biogen ( NASDAQ:BIIB )

Biogen Q1 EPS hit $3.02 vs. $2.52 estimate; revenue rose 6% to $2.43 billion, beating the $2.23 billion consensus. Rare disease sales rose 33% to $563 million; Spinraza revenue climbed to $423.9 million, and Skyclarys reached $123.9 million. Feel unsure about the market's next move?

https://www.benzinga.com/general/biotech/25/05/45147899/biogen-beats-q1-earnings-expectations-as-two-newcomer-drug-sales-spike-avoids-tariff-impact

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.

https://www.zacks.com/stock/news/2460492/biibs-q1-earnings-miss-revenues-top-mark-2025-eps-guidance-cut

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

https://www.zacks.com/stock/news/2459320/sage-therapeutics-q1-earnings-miss-mark-revenue-rise-yy

Trending Today

dogwifhat ($WIF) Crypto Forecast: Up 6.1% Today

EOS ($EOS) Crypto Forecast: Up 8.1% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 6.5% Today

Bumble Inc. ($BMBL) Stock Forecast: Down 5.0% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 8.5% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 5.2% Today

Aave ($AAVE) Crypto Forecast: Up 8.4% Today

Litecoin ($LTC) Crypto Forecast: Up 5.4% Today

American Eagle Outfitters Inc. ($AEO) Stock Forecast: Up 5.1% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 7.2% Today

Biogen Inc. Price History

07.02.2025 - BIIB Stock was up 5.2%

• BIIB stock exhibited a bullish trend despite worries about the pricing of Alzheimer's drugs from Biogen and Eli Lilly.
• Investor optimism towards the potential market demand for Biogen's treatments persists despite pricing concerns.
• The bullish movement reflects confidence in Biogen's capacity to address pricing challenges and advance pioneering therapies in neurology.

01.04.2025 - BIIB Stock was up 3.7%

• BIIB stock surged as investors were impressed by the company's strong performance in the first quarter of 2025.
• Despite Sage Therapeutics' disappointing earnings, BIIB's robust financial results and promising outlook for key metrics exceeded Wall Street estimates, driving up the stock price.
• The market reacted favorably to BIIB's Q1 outlook, indicating confidence in the company's ability to deliver solid results and maintain its position as a key player in the biotech industry.
• Overall, BIIB's bullish movement can be attributed to its strong fundamentals and positive market expectations, contrasting with the underperformance of some of its industry peers.

06.04.2025 - BIIB Stock was down 5.1%

• Following its Q1 earnings release, BIIB witnessed a significant decrease in stock value.
• BIIB outperformed earnings projections, posting an EPS of $3.02 compared to the estimated $2.52, and recorded a revenue surge to $2.43 billion, exceeding the expected $2.23 billion.
• Despite the positive earnings outcome, BIIB's stock faced a decline, potentially due to the mixed Q1 performance and the company's downward revision of its EPS guidance for the year.
• The market response to the revised guidance hints at apprehensions regarding future growth and performance, contributing to the bearish movement in BIIB's stock price today.

15.04.2024 - BIIB Stock was up 5.2%

• BIIB stock surged today due to the FDA granting fast-track designation for its Alzheimer's treatment developed in collaboration with Eisai.
• Eisai initiated the rolling submission of a Biologics License Application (BLA) for the Alzheimer's therapy to the FDA, contributing to the positive market sentiment towards BIIB.
• The advancements in BIIB's Alzheimer's treatment pipeline have increased investor confidence in the company's revenue prospects and competitive stance, resulting in a notable uptick in the stock's performance today.

31.04.2024 - BIIB Stock was up 5.3%

• BIIB stock rose following marketing authorization from the European Commission for Qalsody, a treatment for a rare genetic form of Amyotrophic Lateral Sclerosis (ALS).
• The approval of Qalsody contributed to increased investor confidence in Biogen's product pipeline and potential revenue growth.
• Despite a legal challenge in the form of a securities class action lawsuit, market sentiment was largely driven by the positive EU approval, leading to a bullish trend in BIIB stock.
• This approval highlights Biogen's dedication to addressing medical needs and expanding its range of therapies with innovative solutions.

26.06.2024 - BIIB Stock was down 8.2%

• The rejection of Biogen and Eisai's Alzheimer's drug, lecanemab, by the European Medicines Agency, citing concerns about its efficacy in early-stage Alzheimer's, led to a notable decrease in Biogen's stock value.
• The negative feedback from the Committee for Medicinal Products for Human Use (CHMP) highlighted the regulatory challenges faced by both companies, impacting investor trust in the drug's potential success.
• This rejection emphasizes the difficulties in creating effective Alzheimer's treatments and the necessity for strong clinical evidence to support approval, resulting in a pessimistic outlook on Biogen's stock.
• As attention shifts to Biogen's upcoming second-quarter earnings call, investors are eager to learn how the company plans to address this setback and navigate the regulatory environment for its Alzheimer's therapy.

26.06.2024 - BIIB Stock was down 7.3%

• The rejection of Biogen's Alzheimer's treatment, Leqembi, by the European drug regulator, citing concerns about its effectiveness and serious side effects, likely influenced the bearish market activity in BIIB stock.
• The unfavorable updates on the regulatory evaluation of Lecanemab for Early Alzheimer's Disease in the European Union may have exacerbated investor uncertainty and pushed down the stock price.
• The ongoing inquiry by Bragar Eagel & Squire, P.C. into potential claims against Biogen Inc. might have raised doubts about the company's future, affecting investor confidence and contributing to the bearish market trend.

26.06.2024 - BIIB Stock was down 8.1%

• The rejection of the Marketing Authorization Approval (MAA) for lecanemab by the Committee for Medicinal Products for Human Use (CHMP) in the European Union has significantly impacted Biogen Inc.'s stock performance.
• The negative opinion on lecanemab's effectiveness in treating early Alzheimer's disease has raised concerns among investors about the future prospects of the drug and its potential market success.
• The regulatory hurdles faced by Biogen Inc. and its partner have highlighted the uncertainties surrounding the approval and commercialization of innovative therapies in the healthcare sector.
• The market's reaction to the news reflects the sensitivity of biopharmaceutical stocks to regulatory decisions and underscores the importance of robust clinical data in gaining approval for novel treatments.

04.03.2025 - BIIB Stock was down 5.0%

• BIIB's stock likely dropped due to the positive announcement of its experimental Alzheimer's drug receiving FDA's fast track designation, potentially heightening optimism for its future success.
• Eli Lilly's Alzheimer's drug received a negative assessment from the European Medicines Agency (EMA), indirectly benefitting Biogen by reducing competition in the Alzheimer's treatment sector.
• Investor sentiment appears to favor Biogen over Eli Lilly, given the challenges the latter faces in gaining regulatory approval for its Alzheimer's drug.
• The divergent paths of the two companies in Alzheimer's drug development may have influenced market outlook towards Biogen, contributing to the downward movement in its stock value today.

13.01.2025 - BIIB Stock was up 5.3%

• Biogen reported better-than-expected earnings for its fourth quarter, with adjusted EPS beating consensus estimates.
• Despite the positive earnings report, Biogen's 2025 EPS guidance fell short of expectations, leading to some analyst downgrades.
• The market reacted positively to Biogen's cost-cutting measures and the potential of new drugs like Leqembi, which are expected to offset revenue declines from existing products.
• Overall, the bullish movement in Biogen's stock can be attributed to the company's strong financial performance in Q4, despite some concerns about future earnings guidance.

12.01.2025 - BIIB Stock was down 5.1%

• Despite surpassing earnings and revenue projections in Q4, BIIB experienced a bearish market movement, suggesting potentially elevated market anticipations.
• The projection of profits fell below expectations despite efforts such as cost reductions and the introduction of new medications like Leqembi, indicating possible investor dissatisfaction with the company's future prospects.
• An increase in optimistic positions on BIIB through options trading potentially heightened market volatility and profit-taking, contributing to the downward trend.
• The decrease in sales of multiple sclerosis treatments and Spinraza was balanced by revenues from new drugs, but this may not have met investor expectations, resulting in the bearish market movement.

12.01.2025 - BIIB Stock was down 8.1%

• Biogen exceeded expectations with cost reduction efforts and the launch of Leqembi, but a lower profit outlook caused a decline in the stock price.
• The FDA's approval of a maintenance dosing regimen for Leqembi in Alzheimer's was a positive development, while decreased sales of multiple sclerosis drugs and Spinraza likely impacted revenue.
• Investor optimism in the options market suggests confidence in the long-term potential of Biogen's new drugs, despite short-term profit concerns.
• The forthcoming Q4 earnings report will be essential in offering more insight into the company's financial performance and the effects of new drugs on revenue.